Guggenheim downgraded Immuneering to Neutral from Buy after the company announced topline results from the ongoing Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors, citing “low visibility” and a “changing competitive landscape.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMRX:
- Immuneering Appoints New Director, Advances Cancer Drug Trial
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- Immuneering appoints Thomas Schall to board of directors
- Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
- Immuneering doses first patient in Phase 2a trial of IMM-1-104
